Canada: Agreement To Assign Patents Subject To Act

The Federal Court of Appeal unanimously held that an assignment of a patent may constitute an agreement or arrangement which results in an undue lessening of competition contrary to s. 45 of the Competition Act.

In June, 1997, Eli Lilly and Company and Eli Lilly Canada Inc. (collectively, "Lilly") filed a statement of claim alleging that Apotex Inc. ("Apotex") had infringed several of its patents, including four patents that had previously been assigned to it by Shionogi & Co. Ltd. ("Shionogi") (the "Shionogi Patents"). Each of the Shionogi Patents described and claimed processes suitable for making intermediates which could be converted to the antibiotic, cefaclor, using other non-infringing processes.

Section 45

In 2001, Apotex amended its statement of defence and counterclaim to argue that the assignment of the Shionogi Patents to Lilly violated s. 45 of the Competition Act (the "Act"), which prohibits agreements that prevent or lessen competition unduly. Apotex requested a declaration that the Shionogi Patents were "invalid, void, unenforceable and of no force or effect." It sought damages under subs. 36(1) of the Act. Interestingly, the last of the Shionogi Patents had expired in 2000, and the patent for cefaclor had expired in 1994.

Once Apotex initiated its counterclaim, Lilly and Shionogi brought a series of motions for summary judgment which wound their way through the Federal Court and then the Federal Court of Appeal (the "FCA") through various appeals. Throughout these proceedings, Lilly and Shionogi argued that s. 45 of the Act could not apply as a matter of law to an assignment of patent rights because the Patent Act specifically authorizes holders of patents to assign such rights.

Lilly and Shionogi relied on the FCA's decision in Molnlycke AB v. Kimberly-Clark of Canada Ltd. ("Molnlycke") in which the FCA struck out allegations of anti-competitive activity on the basis that the assignment of a patent involves nothing more than the legitimate exercise of the patentee's monopoly.

Intervenor Status

The Commissioner of Competition (the "Commissioner") applied for and was granted leave to intervene in these proceedings. Her ability to administer the Act in respect of patent rights could be affected by the outcome of the case. In her materials, the Commissioner disagreed with Justice Hugessen's assertion that his decision was consistent with the Competition Bureau's Intellectual Property Enforcement Guidelines (the "IPEGs").

Prior Decisions

Summary Judgment

Initially, a Prothonotary concluded that Molnlycke was distinguishable from the present case in that it involved a different "factual paradigm." It allowed Apotex's claim to proceed. Justice Hugessen disagreed. Following Molnlycke, he concluded that

[the] allegation that Shionogi and Lilly entered into the agreement to assign the Shionogi Patents . . . for the purpose and with the effect of allowing Lilly to continue to have a monopoly of the Canadian market for cefaclor is simply not . .. an allegation of illegal conduct. Everyone who obtains a patent, whether by issue or by assignment, does so for the purpose of obtaining a monopoly which, by definition, is a lessening of competition. That monopoly is one that is legally sanctioned and simply cannot, as a matter of law, result in the lessening of competition being 'undue' during the life of the patent.

Accordingly, Justice Hugessen held that Apotex's counterclaim did not state a cause of action. He granted summary judgment in favour of Lilly and Shionogi.

Reversal On Appeal

On November 2, 2005 the FCA reversed Justice Hugessen's decision, finding the earlier decision in Molnlycke distinguishable from the present case:

[i]n the case of Molnlycke, there was a single supplier lawfully .entitled to sell. the subject of the patent prior to the patent being ssigned. The assignment merely transferred the patent to another company. The only effect of the assignment was that a different company could sue the defendant for infringement. There was no change in the number of patent-holders before and after the assignment.

By contrast, before the assignment of the Shionogi Patents, there were two companies with commercially viable processes for making cefaclor- namely, Shionogi and Lilly. After the assignment, there was only one such company.

Application Of Act

The FCA also pointed out that, in Molnlycke, it had found

that, in order to provide scope for the statutory monopolies - granted by the Patent Act to operate, Parliament must have intended that 'undue impairment of competition cannot be inferred from evidence of the exercise of [patent] rights alone.' Where, however, there is evidence of something more than the mere exercise of patent rights that may affect competition in the relevant market, Molnlyck does not purport to completely preclude application of the [Act].

No Violation

The FCA remanded the matter to Justice Hugessen, who found that the assignment in question did not involve something more than the mere exercise of intellectual property rights; once again, he struck out Apotex's counterclaim.

Federal Court Of Appeal

On Apotex's further appeal, the FCA concluded that Justice Hugessen had erred in law and that Apotex's counterclaim should proceed. The FCA held that the Patent Act does not immunize an agreement to assign a patent from s. 45 of the Act when the assignment increases the assignee's market power in excess of that inherent in the patent rights assigned.

It distinguished Molnlycke, finding that the combination of the assignment of the Shionogi Patents, together with Lilly's already existing ownership of patents for the other commercially viable methods of production for cefaclor, led to a lessening of competition and potentially invoked the application of s. 45.

The FCA noted that: this interpretation of . . . the Patent Act enables it and section 45 of the [Act] to operate harmoniously in accordance with the ordinary meaning of the statutory language of the provisions.

Exemptions And Purpose

The court noted that s. 45 of the Act does not contain any express exception for the exercise of patent rights, in contrast with other provisions of the Act which contain such an exemption. The FCA also noted that

an interpretation of [the Patent Act] which does not immunize the assignment of patents from section 45 when it lessens competition is consistent with the purpose of the [Act].

That purpose, as stated in section 1.1, is to "maintain and encourage" competition. The FCA also noted that this interpretation of the Patent Act is consistent with the enforcement approach set out in the IPEGs.

Meaning Of "Undue"

Alternatively, Lilly and Shionogi argued that, even if s. 45 could apply in theory, it did not apply in practice because the assignment did not lessen competition unduly on the facts of the case. The FCA dismissed this argument; even Justice Hugessen had found at least a lessening of competition in the relevant market on the facts. The FCA stated that the question of whether this lessening of competition was "undue" should be decided at trial.

Limitations And Damages

The FCA also left for resolution at trial the particular issues of whether (i) Apotex's claims were in fact statute-barred because they were beyond the limitation period set out in s. 36 of the Act; and (ii) Apotex had sustained any actual damages, which is another pre-condition for a claim under s. 36.

Even though the assignment took place in 1995, the FCA characterized the conduct as going on "as long as the assignment had competition-lessening effect." This approach, while offered as obiter, differs from the judicial treatment of limitation periods for mergers or other analogous events which typically are viewed as complete once implemented.


The FCA's decision that the Patent Act cannot, in all circumstances, preclude the application of the Competition Act is consistent with the IPEGs and with other international jurisprudence regarding the interplay between antitrust regulation and intellectual property rights.

That said, the decision underscores the careful consideration which must be afforded to competition law issues when licenses or patents are assigned. The assignment of a patent right could land the parties in the middle of an alleged criminal conspiracy, raising the prospect of prosecution and follow- on civil actions.

References: Apotex Inc. v. Eli Lilly and Co., (November 2, 2005) Doc. A-579-04 (F.C .A.); Molnlycke AB v. Kimberly-Clark of Canada Ltd. (1991), 36 C.P.R. (3d) 493

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.